Omnicell, Inc. OMCL R2K

Healthcare · Health Information Services · United States

https://www.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Market & Price

Market Cap

$2.01B

Current Price

$44.14

High / Low (52W)

$51.39 / $26.88

Beta

0.96

Valuation

Stock P/E

100.32

Industry PE

23.65

Forward P/E

20.11

PEG Ratio

15.40

Book Value

$27.36

Price to Book

1.61

P/S

1.64

EV/EBITDA

26.77

Dividend Yield

Profitability & Returns

ROCE

0.34%

ROE

1.63%

ROA

1.21%

Profit Margin

1.67%

Op Margin

5.44%

EPS (Latest Qtr)

$0.25

EPS (TTM)

$0.44

Balance Sheet & Liquidity

Debt/Equity

0.16

Quick Ratio

1.04

Current Ratio

1.50

Debt

$202.18M

Total Assets

$1.97B

Current Assets

$680.07M

Working Capital

$203.46M

Ownership

Promoter Holding

2.14%

Chg in Prom Hold

FII / Inst Holding

105.62%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$1.97B

Total Revenue (TTM)

$1.23B

EBITDA

$73.61M

Free Cash Flow

$112.56M

Operating Cash Flow

$155.88M

Shares Outstanding

45.48M

Gross Margin

43.87%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-2.94%

Profit 5Y

-28.64%

Revenue (YoY)

14.90%

Earnings (YoY)

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 100.3.
Revenue declined at -2.9% CAGR over 5 years.
Earnings shrank at -28.6% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	OMCL Omnicell, Inc. R2K	44.14	100.32	$2.01B	-	0.34%	1.63%	-2.94%	-28.64%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	202.52M	217.41M	228.81M	229.69M	199.62M	213.70M	251.84M	272.74M	296.40M	318.83M	331.39M	348.06M	290.63M	298.97M	298.66M	246.15M	276.79M	282.42M	269.67M	290.56M	310.63M	313.98M	309.88M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	158.73M	162.88M	176.13M	183.66M	169.52M
Gross Profit	49.37M	52.04M	54.49M	56.04M	59.55M	61.69M	57.46M	63.70M	79.94M	78.02M	81.51M	62.19M	78.13M	84.82M	82.45M	88.78M	98.91M	97.12M	104.05M	112.15M	109.62M	83.22M	96.79M	122.28M	136.30M	146.78M	150.05M	158.09M	159.09M	125.03M	134.44M	131.96M	92.62M	114.35M	122.27M	110.94M	127.68M	134.50M	130.32M	140.36M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122.56M	119.56M	126.26M	129.91M	123.51M
Operating Income	9.36M	10.72M	9.95M	12.56M	13.60M	10.38M	12.42M	13.86M	1.85M	-118.00K	4.93M	-16.55M	-701.00K	12.20M	633.00K	7.33M	17.50M	12.76M	18.76M	24.65M	12.15M	-6.99M	10.15M	19.61M	28.92M	29.39M	5.08M	12.48M	18.46M	-22.96M	7.75M	3.71M	-21.85M	3.22M	6.56M	-11.62M	8.12M	8.24M	415.00K	16.85M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.22M	29.77M	29.61M	22.20M	37.35M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9.53M	10.45M	9.70M	699.00K	16.91M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.51M	4.81M	4.24M	2.73M	5.55M
Net Income	-	-	6.19M	7.79M	7.30M	6.32M	8.75M	8.04M	-378.00K	-1.16M	1.98M	-10.34M	1.88M	7.75M	2.72M	6.59M	13.63M	3.28M	15.98M	19.98M	11.31M	-4.30M	8.80M	14.13M	20.42M	29.32M	8.21M	9.07M	16.77M	-15.00M	3.45M	5.55M	-15.68M	3.73M	8.63M	-7.02M	5.64M	5.46M	-2.03M	11.36M
Diluted EPS	0.17	0.21	0.17	0.21	0.20	0.17	0.24	0.22	-0.01	-0.03	0.05	-0.28	0.05	0.20	0.07	0.16	0.33	0.08	0.37	0.46	0.26	-0.10	0.20	0.30	0.43	0.61	0.17	0.20	0.37	-0.33	0.08	0.12	-0.34	0.08	0.19	-0.15	0.12	0.12	-0.05	0.25
R&D Expense	7.15M	6.56M	6.12M	6.47M	7.08M	8.02M	8.75M	9.18M	13.84M	13.79M	15.26M	16.80M	16.91M	16.41M	16.54M	15.51M	15.80M	16.08M	16.85M	16.62M	18.65M	20.83M	15.20M	16.08M	18.21M	19.48M	25.03M	26.36M	25.17M	22.88M	23.14M	24.28M	22.06M	21.10M	21.21M	20.53M	21.57M	24.02M	-	21.52M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	695.91M	712.71M	787.31M	897.03M	892.21M	1.13B	1.30B	1.15B	1.11B	1.18B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	706.96M	650.27M	641.24M	681.40M
Gross Profit	105.22M	117.92M	135.78M	170.59M	203.40M	233.86M	247.93M	317.08M	318.64M	372.33M	436.91M	413.29M	554.65M	588.99M	496.84M	471.00M	503.44M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	591.31M	531.71M	470.67M	498.28M
Operating Income	669.00K	9.53M	16.22M	27.13M	35.30M	49.58M	48.63M	21.41M	11.14M	44.39M	78.35M	35.53M	89.51M	-2.32M	-34.87M	337.00K	5.16M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	96.85M	60.69M	90.09M	91.79M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.45M	-20.11M	25.59M	11.32M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-8.10M	263.00K	13.06M	9.27M
Net Income	-	4.89M	10.39M	16.18M	23.98M	30.52M	30.76M	9.76M	30.52M	37.73M	61.34M	32.19M	77.85M	5.65M	-20.37M	12.53M	2.05M
Diluted EPS	0.01	0.15	0.30	0.47	0.67	0.83	0.84	0.26	0.79	0.93	1.43	0.74	1.62	0.12	-0.45	0.27	0.04
R&D Expense	17.57M	21.01M	22.04M	23.73M	29.11M	27.80M	35.16M	57.80M	66.02M	64.84M	68.64M	70.16M	75.72M	104.97M	97.11M	90.41M	88.67M

Compounded Sales Growth

5 Years:	-2.94%
1 Year:	14.90%

Compounded Profit Growth

5 Years:	-28.64%
1 Year:	-

Stock Price Performance

1 Year:	+45.34%
6 Months:	+19.30%
3 Months:	+7.40%
1 Month:	+2.41%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	343.22M	363.85M	441.82M	492.50M	560.21M	578.75M	935.10M	1.02B	1.08B	1.24B	1.82B	-	2.21B	2.23B	2.12B	1.97B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	881.81M	927.57M	815.49M	680.07M
Cash & Equivalents	120.44M	169.23M	175.63M	191.76M	62.31M	104.53M	125.89M	82.22M	54.49M	32.42M	67.19M	127.21M	485.93M	-	330.36M	467.97M	369.20M	196.52M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147.55M	110.10M	88.66M	100.91M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	299.47M	252.03M	256.40M	216.86M
Total Liabilities	-	-	78.01M	80.94M	134.27M	143.50M	170.12M	176.36M	503.50M	462.02M	401.62M	395.56M	857.00M	-	1.08B	1.04B	877.65M	742.91M
Current Liabilities	-	-	58.16M	60.63M	83.08M	92.40M	112.33M	124.63M	180.91M	205.21M	204.58M	237.00M	276.42M	-	428.45M	367.79M	595.68M	476.61M
Long Term Debt	-	-	-	-	-	-	-	0	245.73M	194.92M	135.42M	50.00M	-	-	566.57M	569.66M	166.40M	167.60M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	616.74M	614.09M	382.55M	204.34M
Total Equity	233.56M	242.30M	265.21M	282.91M	307.55M	349.00M	390.10M	420.46M	458.84M	554.34M	679.62M	845.25M	967.50M	-	1.13B	1.19B	1.24B	1.23B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.03M	55.82M	56.66M	57.83M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	39.48M	55.26M	65.16M	38.49M	49.90M	24.83M	103.97M	145.01M	185.87M	-	77.78M	181.09M	187.72M	127.30M
Investing Cash Flow	-	-	-	-168.71M	-20.45M	-43.33M	-45.60M	-341.32M	-34.99M	-54.37M	-61.66M	-279.87M	-	-58.67M	-55.02M	-52.79M	-60.36M
Financing Cash Flow	-	-	-	-232.00K	7.37M	-206.00K	-36.56M	263.75M	-9.88M	-13.60M	-23.48M	456.27M	-	-20.95M	23.42M	-235.58M	-218.32M
Capital Expenditure	-3.65M	-6.89M	-8.69M	-15.12M	-12.34M	-11.92M	-7.54M	-13.45M	-15.34M	-23.70M	-15.89M	-22.84M	-	-60.74M	-55.02M	-52.79M	-57.93M
Free Cash Flow	-	-	-	24.36M	42.93M	53.24M	30.94M	36.45M	9.49M	80.27M	129.11M	163.03M	-	17.04M	126.08M	134.93M	69.37M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.84M	149.50M	-100.65M	-151.38M
Share Buybacks	-	0	12.57M	12.36M	20.96M	24.09M	50.02M	0	0	0	0	53.03M	0	52.21M	0	0	77.60M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	45.6%	44.7%	47.3%	48.7%	46.3%	49.0%	45.4%	43.3%	42.3%	42.5%
Operating Margin %	-	-	-	-	-	-	-	3.1%	1.6%	5.6%	8.7%	4.0%	7.9%	-0.2%	-3.0%	0.0%	0.4%
Net Margin %	-	-	-	-	-	-	-	1.4%	4.3%	4.8%	6.8%	3.6%	6.9%	0.4%	-1.8%	1.1%	0.2%
ROE %	-	1.8%	3.7%	5.3%	6.9%	7.8%	7.3%	2.1%	5.5%	5.6%	7.3%	3.3%	-	0.5%	-1.7%	1.0%	0.2%
ROCE %	-	3.3%	5.3%	7.6%	8.8%	11.1%	10.7%	2.8%	1.4%	5.1%	7.8%	2.3%	-	-0.1%	-1.9%	0.0%	0.3%

Shareholding Pattern

Insiders

2.14%

Institutions

105.62%

Public Float

107.93%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.85%	7.21M	$318.13M
2	Vanguard Portfolio Management LLC	7.07%	3.21M	$141.90M
3	Wellington Management Group, LLP	5.95%	2.71M	$119.49M
4	Dimensional Fund Advisors LP	5.39%	2.45M	$108.16M
5	Millennium Management Llc	5.03%	2.29M	$101.02M
6	State Street Corporation	4.29%	1.95M	$86.10M
7	Vanguard Capital Management LLC	4.25%	1.93M	$85.39M
8	Lazard Asset Management LLC	3.23%	1.47M	$64.89M
9	Sumitomo Mitsui Trust Group, Inc.	3.10%	1.41M	$62.28M
10	Nomura Asset Management International Inc	2.60%	1.18M	$52.24M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OMCL

No recent headlines available.

OMCL · Healthcare

Omnicell, Inc.

About

Key Facts

Sector	Healthcare
Industry	Health Information Services
Headquarters	United States
Employees	3,525
Website	https://www.omnicell.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Omnicell, Inc. OMCL R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More